Page 15 – Redenlab

Simons Searchlight: Researcher Profile: Angela Morgan, PhD

Posted on March 30, 2023
by Gloria Macan
Blog, News

Angela Morgan, PhD, is a National Health and Medical Research Council Elizabeth Blackburn Fellow and leads the Speech and Language group at the Murdoch Children’s Research Institute in Melbourne, Australia. Morgan is also a Dame…

Posted on March 30, 2023
by Gloria Macan
Blog, Clinical trial/studies, Dementia, News, Speech

Redenlab are partnering with Monash university, University of Melbourne, Eastern Health, and Invicta to deliver this world-first collaboration investigating neurofilament light chain and voice for diagnosing dementia. Funded by the Medical Research Future Fund, the…

Posted on April 27, 2023
by Gloria Macan
Clinical Study, Clinical trial/studies, clinical trials, Language, News, Speech, Voice

MEDIA RELEASERedenlab, a leading techbio company, proudly announces its recent feature on the highly acclaimed Huberman Podcast. The podcast episode sheds light on Redenlab's groundbreaking research on the effects of cannabis on the brain and…

Posted on July 13, 2023
by Gloria Macan
Blog, News

Redenlab are thrilled to announce that Dr. Peter Gibilisco has joined Redenlab's advisory board. As a consumer advisor with profound insights into the importance of speech and its changes with disease, Dr. Gibilisco brings invaluable…

Posted on August 11, 2023
by Redenlab
Clinical Study, Clinical trial/studies, clinical trials, Language, News, Speech

Dentatorubral-pallidoluysian atrophy (DRPLA) is a rare progressive brain disorder that can impact children and adults. In children, DRPLA can lead to difficulties walking, talking, eating, epilepsy, and progressive intellectual deterioration. In adults, it manifests as…

Posted on September 14, 2023
by Gloria Macan
children, Clinical Study, Clinical trial/studies, clinical trials, Language, Morgan, News, Speech

Redenlab, a leading provider of innovative solutions in the field of pediatric and neurodevelopment communication, proudly announces that Professor Angela Morgan, the Director of Pediatric/Neurodevelopment Communication at Redenlab, will lead the Translational Centre for Speech…

Posted on October 24, 2023
by Gloria Macan
Ataxia, Clinical Study, Clinical trial/studies, clinical trials, Language, News, Publications, Speech

Friedreich ataxia (FA) is an inherited, multisystem neurodegenerative disease that results in profound changes to speech, swallowing, balance, walking, cardiac health and upper limb function. TRACK-FA is an imaging study focussed on building a better…

Posted on October 24, 2023
by Gloria Macan
Ataxia, Clinical Study, Clinical trial/studies, clinical trials, Language, News, Speech

Friedreich ataxia (FA) is a progressive, genetically inherited multisystem disease that affects children and adults. FA leads to significant changes to an individual’s ability to walk, talk, eat and drink. The FA App is a…

Posted on October 24, 2023
by Gloria Macan
Ataxia, Clinical Study, Clinical trial/studies, clinical trials, Language, News, Speech

Spinocerebellar ataxia Type 1 (SCA1) is a dominantly inherited neurodegenerative disease resulting in balance, speech, thinking and coordination difficulties. SCA1 is one of the more common ataxias, with onset typically in the fourth and fifth…

Posted on October 24, 2023
by Gloria Macan
children, Clinical Study, Clinical trial/studies, clinical trials, Language, News, Speech

Speech disorders impacting children have debilitating impacts on educational, social and later employment outcomes. There are limited therapeutic options for children and families to improve speech like apraxia, and no pharmaceutical treatments are available. There…

Simons Searchlight: Researcher Profile: Angela Morgan, PhD

Redenlab selected for world-first international collaboration investigating neurofilament light chain and voice for diagnosing dementia

Redenlab shines in Huberman Podcast, unveiling cannabis study and speech analysis expertise

Redenlab welcomes Dr. Peter Gibilisco to our advisory board, reinforcing our patient-centred approach

Academic and patient advocacy group collaborations in Dentatorubral-pallidoluysian atrophy (DRPLA)

Professor Angela Morgan leads the Translational Centre for Speech Disorders in groundbreaking NHMRC CRE research program

TRACK-FA Study

The FA App

Researchers working towards finding a new treatment for Spinocerebellar Ataxia Type 1 (SCA1)

Childhood apraxia of speech clinical trial

Categories